Samir Parekh, MD, on Improving Survival in Multiple Myeloma With Sequential T-Cell Redirection Therapies


The director of translational research in myeloma at the Tisch Cancer Institute discussed positive findings, including a 30-month PFS in study participants.

“The question to us as both clinicians and researchers was, how can we treat these patients; what will be the best sequential therapy after the bispecific when patients relapse? And this is important because it could inform how we could move them in earlier lines of therapy and what to do with patients that relapse even if they get it in earlier lines of therapy.”

Sequential use of different T cell redirection therapies, including chimeric antigen receptor (CAR) T-cell therapies, after relapsed on bispecific antibodies (BiAb) led to deep and durable responses in patients with relapsed/refractory multiple myeloma, according to new research published in Blood Advances.

CGTLive spoke with Samir Parekh, MD, to learn more about the new research out of at Mount Sinai’s Tisch Cancer Institute. Parekh serves as director of translational research in myeloma and co-leader of the Cancer Clinical Investigation program at The Tisch Cancer Institute andis a member of the Icahn Genomics Institute at the Icahn School of Medicine at Mount Sinai. Parekh discussed the research that his team conducted and the positive progression-free survival findings for patients on sequential T-cell redirection therapies.

Mouhieddine TH, Oekelen OV, Melnekoff DT, et al. Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients. Blood Adv. Published online August 2, 2022. doi: 10.1182/bloodadvances.2022007923
Related Videos
Julie Kanter, MD
Mark Walters, MD
Ula V. Jurkunas, MD
Alfonso Sabater, MD, PhD, on Bringing Gene Therapy to Ophthalmology
Sharon Hesterlee, PhD
© 2023 MJH Life Sciences

All rights reserved.